THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 96 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $444,296 | -52.4% | 44,489 | -46.5% | 0.00% | -50.0% |
| Q4 2022 | $933,483 | -10.5% | 83,202 | -19.1% | 0.01% | -14.3% |
| Q3 2022 | $1,043,000 | -84.9% | 102,828 | -78.4% | 0.01% | -85.1% |
| Q2 2021 | $6,907,000 | -1.7% | 475,696 | +71.3% | 0.05% | -39.7% |
| Q1 2020 | $7,028,000 | -2.3% | 277,700 | 0.0% | 0.08% | +1.3% |
| Q4 2019 | $7,190,000 | +32.0% | 277,700 | -0.7% | 0.08% | +6.9% |
| Q3 2019 | $5,449,000 | +19.8% | 279,700 | 0.0% | 0.07% | +26.3% |
| Q2 2019 | $4,547,000 | -28.3% | 279,700 | 0.0% | 0.06% | -29.6% |
| Q1 2019 | $6,341,000 | -11.4% | 279,700 | 0.0% | 0.08% | -26.4% |
| Q4 2018 | $7,157,000 | -14.0% | 279,700 | +9.8% | 0.11% | -0.9% |
| Q3 2018 | $8,321,000 | +1114.7% | 254,700 | +1173.5% | 0.11% | +825.0% |
| Q3 2017 | $685,000 | -42.7% | 20,000 | -33.3% | 0.01% | -45.5% |
| Q2 2017 | $1,195,000 | -53.6% | 30,000 | -57.1% | 0.02% | -56.0% |
| Q1 2017 | $2,578,000 | +7.8% | 70,000 | -6.7% | 0.05% | -9.1% |
| Q4 2016 | $2,391,000 | – | 75,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |